Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination

Yamamoto,Manabu; Matsuyama,Ayumi; Yoshinaga,Keiji; Iwasa,Tokiomi; Tsutsui,Shinichi; Ishida,Teruyoshi

doi:10.3892/ol.2011.525

Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination

Authors:
- Manabu Yamamoto
- Ayumi Matsuyama
- Keiji Yoshinaga
- Tokiomi Iwasa
- Shinichi Tsutsui
- Teruyoshi Ishida
View Affiliations

Affiliations: Department of Surgery, Hiroshima Red Cross Hospital, Naka-ku, Hiroshima 730-8619, Japan
Published online on: December 14, 2011 https://doi.org/10.3892/ol.2011.525
Pages: 662-666

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Systemic chemotherapy is the key treatment for patients presenting with advanced gastric cancer with peritoneal dissemination. In certain cases, adjuvant surgery following systemic chemotherapy may result in improved long-term survival. This study aimed to evaluate the efficacy of adjuvant surgery following response to chemotherapy for advanced gastric cancer with peritoneal dissemination. The study included 13 patients with a diagnosis of advanced gastric cancer with peritoneal dissemination. Of the 13 patients, 5 patients underwent surgery after the peritoneal dissemination was eradicated following systemic chemotherapy (group S), while the remaining 8 patients continued to receive systemic chemotherapy due to persistent peritoneal dissemination (group C). All 13 patients underwent treatment between October 2008 and February 2011. The chemotherapy regimen included cis-diamminedichloride platinum plus S-1 (an oral fluoropyrimidine) or docetaxel plus S-1 for all patients. The median overall survival time of the 13 patients was 660 days. The survival time did not differ with patient response to chemotherapy. The median survival time of the patients in group S was 794 days, which was significantly higher than that of the patients in group C (505 days; p<0.05). One- and 2-year survival was observed in 100 and 60% of patients, respectively, in group S, and 66.7 and 0% of patients in group C. In conclusion, adjuvant surgery led to longer survival in patients having advanced gastric cancer with peritoneal dissemination, which was eradicated following systemic chemotherapy.

View Figures

View References

1	Kamanger F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparties in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
2	Inoue M and Tsugane S: Epidemiology of gastric cancer in Japan. Postgrad Med J. 81:419–424. 2005. View Article : Google Scholar
3	Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
4	Glinelinus B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H and Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 8:163–168. 1997. View Article : Google Scholar : PubMed/NCBI
5	MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R and Lagarde C: 5-Fluorouracil, doxorubicin, and mitomycin (fam) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 93:533–536. 1997. View Article : Google Scholar : PubMed/NCBI
6	Findlay M, Cuningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R and Hill A: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 5:609–616. 1994.PubMed/NCBI
7	Ohtsu A, Shimoda Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H and Yoshida S: Randomized phase III trial of fluorouracil alone vs. fluorouracil plus cisplatin vs uracil and tergafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Study (JCOG9205). J Clin Oncol. 21:54–59. 2003. View Article : Google Scholar
8	Koizumi W, Narahara H, Hara T, Takegane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin vs. S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS): A phase III trial. Lancet Oncol. 9:215–221. 2009. View Article : Google Scholar : PubMed/NCBI
9	Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J and Ohtsu A: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil vs. combination of irinotecan plus cisplatin vs S-1 in metastatic gastric cancer A randomized phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
10	Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA and Benson AB 3rd: Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol el293. Med Oncol. 13:87–93. 2006. View Article : Google Scholar
11	Thuss-Patience PC, Kretzchmar A and Reichardt P: Docetaxel in the treatment of gastric cancer. Future Oncol. 10:603–620. 2009.
12	Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J and Ohta T: Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer with para-aortic lymph node metastases. Anticancer Drug. 20:752–756. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, et al: Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 64:877–883. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M and Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res. 24:1843–1851. 2004.PubMed/NCBI
15	Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Toda S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced gastric cancer. Clin Cancer Res. 12:3402–3407. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kim YH, Koizumi W, Lee KH, Kishimoto T, Chung HC, Hara T, Cho JY, Nakajima T, Kim H and Fujii M: American Society of Clininal Oncology – Gastrointestinal Symposium 2011, Board #A8. J Clin Oncol. 29(Suppl 4): abs. 72011.
17	Eisenhauer EA, Terasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
18	Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma − 3rd English edition. Gastric Cancer. 14:101–112. 2011.
19	Trotti A, Colevas AD, Setser A, Rusch H, Jaques D, Budach V, Langer C, Murphy B, Cumberline R, Coleman CN and Rubin P: CTCAC v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 13:176–181. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT and Ajiani JA: Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 109:33–40. 2008. View Article : Google Scholar : PubMed/NCBI
21	Park SR, Kim HK, Kim CG, Choi IJ, Lee JS, Lee JH, Ryu KW, Kim YW, Bae JM and Kim NK: Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer. 98:1305–1311. 2008. View Article : Google Scholar : PubMed/NCBI
22	Suzuki T, Tanabe K, Taomoto J, Yamamoto H, Tokumoto N, Yoshida K and Ohdan H: Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. 1:743–747. 2010.PubMed/NCBI
23	Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Fukukawa H, Nakajima T, Ohashi Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J M. 357:1810–1820. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kodera Y, Ishikawa A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, Michizuki Y, Ito H, Tsuburaya A, Sakamoto J and Nakao A: A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma. Gastric Cancer. 13:197–203. 2010. View Article : Google Scholar : PubMed/NCBI
25	Fushida S, Fujimura T, Oyama K, Kinoshita J, Fujita H, Ninomiya I and Ohta T: Neoadjuvant chemotherapy combining docetaxel, cisplatin, and S-1 in gastric cancer with para-aortic lymph node metastases: report of five cases. Hepatogastroenterol. 57:1650–1654. 2010.PubMed/NCBI